Coghlan, John Gerry <br/><br/>
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.  [electronic resource] 

 -  Annals of the rheumatic diseases  Jul 2017 
 - 1219-1227 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/annrheumdis-2016-210236  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antihypertensive Agents--therapeutic use<br/>Disease Progression<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Edema--chemically induced<br/>Female<br/>Humans<br/>Hypertension, Pulmonary--drug therapy<br/>Lupus Erythematosus, Systemic--complications<br/>Male<br/>Middle Aged<br/>Mixed Connective Tissue Disease--complications<br/>Phenylpropionates--therapeutic use<br/>Phosphodiesterase 5 Inhibitors--therapeutic use<br/>Pyridazines--therapeutic use<br/>Scleroderma, Systemic--complications<br/>Tadalafil--therapeutic use